Mar 24 |
Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?
|
Mar 20 |
Vigil Neuroscience appoints Kaufmann as Chief Medical Officer
|
Mar 20 |
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
|
Mar 12 |
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
|
Mar 6 |
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
|
Feb 29 |
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024
|
Jan 4 |
Vigil Neuroscience remains on track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024
|
Jan 3 |
Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones
|
Nov 21 |
Vigil Neuroscience: Interim Data Sheds Light On Possible Accelerated Pathway
|
Nov 17 |
Why Is Rare Neurological Disease Focused Vigil Neuroscience Stock Trading Lower Today?
|